Nature Biotechnology
30(10), 2012

Innovative drugs and vaccines in China, India and Brazil.
Rahim Rezaie, Anita M. McGahan, Abdallah S. Daar and Peter A. Singer..

http://www.nature.com/nbt/journal/v30/n10/full/nbt.2380.html

Just how much innovation is going on within private-sector enterprises in emerging markets? What is the nature of these innovations? Who are the companies in China, India and Brazil innovating for? These are some of the questions addressed in this article. The article details 165 innovative vaccines and medicines in the pipeline of 41 domestic companies in the stated countries. It concludes that: a) a growing number of domestic health enterprises in the stated countries are developing innovative medicines and vaccines, and b) as a group they exhibit a predilection for diseases that are most relevant domestically. It foresees that the rising innovation capacity in emerging markets will have a major effect not only on developing world health systems but also health systems in the developed world, especially as the latter struggle with escalating costs.